Biogen Idec dumps Dompe to manage costs in Italian and Swiss MS market
This article was originally published in Scrip
Executive Summary
Biogen Idec is acquiring all of the shares of the two joint ventures it has had with Italian biotechnology company, Dompe Group, for the multiple sclerosis drugs Avonex (interferon beta-1) and Tysabri (natalizumab) in Italy and Switzerland, thereby increasing the number of countries in which it has a direct commercial presence to 29.